EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Burosumab Efficacy and Safety in Patients with X-Linked Hypophosphatemia: Systematic Review and Meta-analysis of Real-World Data

Damiani Kiafzezi, Athina Stamati, Thomas Karagiannis, Dimitrios G Goulis, Athanasios Christoforidis

Calcified Tissue International · 2024

DOI: 10.1007/s00223-024-01250-z ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Calcified Tissue International, 2024. Verfasst von Damiani Kiafzezi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Program "Research Methodology in Medicine and Health Sciences", Aristotle University of Thessaloniki, Thessaloniki, Greece. kiafdami@gma…. Hauptthemen laut MEDLINE: Familial Hypophosphatemic Rickets, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To assess the efficacy and safety of burosumab in children and adults with X-linked hypophosphatemia based on real-world evidence. MEDLINE (via PubMed) and Cochrane Library were searched until 18 October 2023 for single-arm (before-after) studies. Registries including Clinicaltrials.gov, EU Clinical Trials, WHO International Clinical Trials Registry Platform, and conference abstracts. The outcomes were a change in serum phosphorus concentrations and change in RSS, a change in serum ALP, bone-specific ALP, a change in the ratio of Tubular maximum reabsorption of Phosphate to Glomerular Filtrate rate, a change in serum 1,25(OH)2D and 25(OH)2D concentrations, change in height Z-score, McMaster Universities Osteoarthritis Index (WOMAC) and safety outcomes. An inverse variance random-effects meta-analysis was applied for data synthesis. Fifteen studies (289 participants) were included. Burosumab treatment improved serum phosphate concentrations [mean difference 0.88 mg/dl, 95% confidence interval 0.70 to 1.07, I2 = 92%), Rickets Severity score (mean difference - 1.86, 95% confidence interval - 2.5 to - 1.21, I2 = 71%), serum alkaline phosphate concentrations (mean difference - 1.86, 95% confidence interval - 2.5 to - 1.21, I2 = 71%), serum 1,25(OH)2D concentrations (mean difference 18.91 pg/ml, 95% confidence interval 6.39 to 31.43, I2 = 96%) and renal phosphate reabsorption (mean difference 1.22 mg/dl, 95% confidence interval 0.70 to 1.74, I2 93%). Burosumab treatment improved overall clinical and laboratory findings in patients with X-linked hypophosphatemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Familial Hypophosphatemic RicketsAntibodies, Monoclonal, HumanizedHumansTreatment OutcomePhosphates

Stichwörter der Autor:innen

BurosumabMeta-analysisSystematic reviewX-linked hypophosphatemiaXLH

Substanzen

burosumabAntibodies, Monoclonal, HumanizedPhosphates

Autor:innen und Institutionen

  • Postgraduate Program "Research Methodology in Medicine and Health Sciences", Aristotle University of Thessaloniki, Thessaloniki, Greece. kiafdami@gmail.com.
  • School of Medicine, Faculty of Health Science, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Diabetes Centre, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, 541 24, Thessaloniki, Greece.
  • 1st Paediatric Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Ippokratio General Hospital, Thessaloniki, Greece.

Zitieren

APA

Kiafzezi, D., Stamati, A., Karagiannis, T., Goulis, D. G., & Christoforidis, A. (2024). Burosumab Efficacy and Safety in Patients with X-Linked Hypophosphatemia: Systematic Review and Meta-analysis of Real-World Data. Calcified Tissue International. https://doi.org/10.1007/s00223-024-01250-z

Vancouver

Kiafzezi D, Stamati A, Karagiannis T, Goulis DG, Christoforidis A. Burosumab Efficacy and Safety in Patients with X-Linked Hypophosphatemia: Systematic Review and Meta-analysis of Real-World Data. Calcified Tissue International. 2024. doi:10.1007/s00223-024-01250-z

BibTeX
@article{Kiafzezi2024,
  author = {Kiafzezi, Damiani and Stamati, Athina and Karagiannis, Thomas and Goulis, Dimitrios G and Christoforidis, Athanasios},
  title = {Burosumab Efficacy and Safety in Patients with X-Linked Hypophosphatemia: Systematic Review and Meta-analysis of Real-World Data},
  journal = {Calcified Tissue International},
  year = {2024},
  doi = {10.1007/s00223-024-01250-z}
}
Kostenlos starten →